Extracorporeal assist systems for respiratory and circulatory failure are increasingly used in intensive care medicine. Important technical innovations over the past years have resulted in improved biocompatibility and, consequently, reduced complication rates. Extracorporeal membrane oxygenation (ECMO) technology experienced a surge of use during the influenza A (H1N1) pandemic, but transport of unstable patients with life-threatening ARDS is still hazardous. We describe the first successful application of a newly developed, compact and easily portable ECMO device in a patient with severe ARDS due to influenza A (H1N1). Support with the miniaturized ECMO resulted in immediate improvement of gas exchange and a highly protective ventilation. Inspiratory pressure was decreased from 40 to 29 cmH 2 O and tidal volume per kilogram of predicted bodyweight could be reduced from 6.5 to 3.3 mL.
Introduction
The first successful application of extracorporeal membrane oxygenation (ECMO) for lung failure in a trauma patient was published in 1972 1 . Important technical innovations in recent years have led to an increasing use of extracorporeal devices to support circulatory and pulmonary function. In 2009, a randomized trial in adult patients with acute respiratory distress syndrome (ARDS) treated with ECMO indicated a significantly improved survival without disability compared to conventional ventilation support 2 . Transport of patients on ECMO from referring centres had not been possible in this trial. Lately, the employment of ECMO to patients with influenza A (H1N1)-associated respiratory failure showed an impressive overall survival 3 . Miniaturized devices for extracorporeal gas exchange showed reduced complication rates and allowed successful use of ECMO in patients with thrombocytopenia and risk of hemorrhage 4 .
We report on the worldwide first application in men of a new compact, portable ECMO device with integrated pump and oxygenator in a patient with severe life-threatening ARDS due to influenza A (H1N1) in May 2010.
Case Report
A 30-year-old female patient (body mass index (BMI) 49.5 kg/m²) presented to another hospital with progressive dyspnea and elevated temperature up to 40°C of five days' duration. Her past history was unremarkable apart from asthma controlled with inhaled steroids. She was admitted to the intensive care unit and needed immediate intubation for worsening hypoxia. Her condition deteriorated rapidly and she was transferred to our center the same night. On admission, the patient was in need of vasopressors and invasive mechanical ventilation, with inspiratory pressures up to 47 cmH 2 O, severe respiratory acidosis and marginal oxygenation at an FiO 2 of 1.0 (Table1). Inflammatory parameters (procalcitonin 3.73 ng/mL, normal <0.1 ng/mL) and lactic dehydrogenase (LDH 1143 U/L, normal <247 U/L) were elevated; severe rhabdomyolysis was present (creatinine kinase 9721 U/L, normal <167 U/L) with consequent acute renal failure. As stabilization with conventional methods was not possible, despite a trial to optimize mechanical ventilation for several hours, no improvement occurred on prone positioning or inhaled vasodilators and the chest X-ray indicated severe ARDS ( Figure 1 ), we decided to use extracorporeal respiratory support to improve gas exchange and to avoid prolonged aggressive ventilation.
The right femoral and the right internal jugular veins were cannulated with a long 22-Fr cannula (Maquet-Cardiopulmonary-AG, Hirrlingen, Germany) and a short 17-Fr cannula (NovaLung-GmbH, Talheim, Germany) in the Seldinger technique. Extracorporeal membrane oxygenation was achieved with the newly developed Cardiohelp (Maquet-Cardiopulmonary-AG, Hirrlingen, Germany), which has been used for the first time ( Figure 2 , during transport to the computerized tomography (CT) scan). This device has a gas exchange surface area of 1.8 m², a heat exchange surface area of 0.4 m² and a priming volume of about 600 mL. The diffusion membrane of the oxygenator is made of polymethylpentene and the system is heparin coated (Bioline Coating™) from tip to tip. After initiation of the extracorporeal support, invasiveness of mechanical ventilation could be decreased immediately; respiratory parameters before, during and after ECMO are presented in Table 1 . The polymerase chain reaction (PCR) for Influenza A-H1N1-RNA 5 proved to be positive in the bronchiolo-alveolar lavage (BAL) the same day (10 7 copies) and therapy with oseltamivir 150 mg tid was started. After 10 days, the PCR-test was still positive (10 4 copies), but after 17 days it proved to be negative in the BAL.
Further clinical course was complicated by a hemorrhage into the right thigh due to difficult cannulation, which was controlled conservatively with reduced heparin dosing and an intended activated partial thromboplastin time (aPTT) of 40-45 seconds. The maximum decrease of platelets from initial values was less than 20% during ECMO therapy ( Table 2 ). After early tracheotomy, sedation was tapered and the patient was supported with neurally adjusted ventilatory assist (NAVA) in a highly protective mode. Due to reduced anticoagulation, the oxygenator had to be exchanged once after 1 week of therapy. This was accomplished in less than one minute, without deterioration of the patient during the exchange, as FiO 2 was temporarily increased. Weaning from ECMO support was possible on the 12th day of ECMO treatment after first slowly reducing blood flow to 1.5 L/min and sweep gas flow to 1 L/min. Thereafter, sweep gas flow was paused for 1 hour and ECMO was removed, as the patient remained stable. Renal function returned after two weeks and the patient was discharged from the ICU after 21 days, with uneventful further recovery.
Discussion
Extracorporeal membrane oxygenation is becoming increasingly recognized as a potentially life-saving technique to secure vital gas transfer in life-threatening respiratory failure. During the Influenza A-(H1N1) pandemic, intensivists throughout the world used ECMO for the most severe cases of viral pneumonia. ECMO not only secures gas transfer, but also allows highly protective ventilation. It can be assumed that, thereby, the magnitude of ventilator-induced lung injury will be reduced and time is gained for the diseased lung to heal.
Historic ECMO trials could not demonstrate a significant reduction of mortality in adults 6, 7 . This was mainly caused by the need for a pronounced systemic anticoagulation due to the large foreign surface of early devices, which resulted in severe bleeding complications. In contrast, modern devices are characterized by a largely improved biocompatibility, with reduced artificial surfaces, heparin coating, plasma-resistant gas exchange membranes and centrifugal pumps. The new Cardiohelp heart-lung assist system integrates all components of ECMO into one compact device which is portable with a weight of less than 13 kg. Therefore, intra-hospital ( Figure 2 ) and inter-hospital transport is greatly facilitated. Transfer of patients to specialized centers with ECMO support, who would otherwise be too unstable for transport, is becoming increasingly important 8 . With the new device, saturation of inflowing central venous blood, hemoglobin and hematocrit are recorded continuously. Thus, central venous saturation presents information about swings in oxygen consumption in the course of the disease. The online documentation of inflow pressure values, recorded with stop-cock-free pressure chips, is helpful with respect to the need of volume substitution to increase venous filling. Transmembrane pressures, acquired automatically, can be useful to guide the necessity of an oxygenator-exchange.
Small and efficient heart-lung assist systems will probably become a tool of growing importance in intensive care medicine in the future. Not only will they be applied in severe hypoxemic and/or hypercapnic respiratory failure to decrease aggressiveness of invasive ventilation, but will also be used more often in circulatory failure. For cardiogenic shock and circulatory arrest unresponsive to conventional therapy, veno-arterial ECMO has been used successfully 9, 10 . Pesenti and colleagues recently have been looking forward to further improvements in extracorporeal gas exchange technology, which had undergone huge progress in the last 30 years 11 . We believe this new device, whose first clinical application in the world has been described here, will pave the way for new developments. (CK = creatinine kinase, LDH = lactic dehydrogenase, AST = aspartatetransferase, ALT = alaninetransferase, Crea = creatinine)
